KemPharm (KMPH) Hits New 52-Week Low at $1.60

KemPharm Inc (NASDAQ:KMPH) reached a new 52-week low during trading on Thursday . The company traded as low as $1.60 and last traded at $1.63, with a volume of 2850 shares. The stock had previously closed at $1.64.

Separately, Zacks Investment Research cut KemPharm from a “hold” rating to a “sell” rating in a research note on Tuesday, January 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $10.75.

The firm has a market cap of $42.96 million, a PE ratio of -0.65 and a beta of 1.72.

Several large investors have recently made changes to their positions in KMPH. Janney Montgomery Scott LLC bought a new position in shares of KemPharm in the fourth quarter worth about $44,000. Change Path LLC bought a new position in shares of KemPharm in the fourth quarter worth about $67,000. Wedbush Securities Inc. bought a new position in shares of KemPharm in the first quarter worth about $72,000. Northern Trust Corp raised its stake in shares of KemPharm by 34.0% in the fourth quarter. Northern Trust Corp now owns 43,445 shares of the specialty pharmaceutical company’s stock worth $78,000 after buying an additional 11,014 shares during the period. Finally, BlackRock Inc. raised its stake in shares of KemPharm by 25.0% in the fourth quarter. BlackRock Inc. now owns 90,426 shares of the specialty pharmaceutical company’s stock worth $161,000 after buying an additional 18,079 shares during the period. 34.72% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This report was originally published by Markets Daily and is the property of of Markets Daily. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.themarketsdaily.com/2019/04/18/kempharm-kmph-hits-new-52-week-low-at-1-60.html.

About KemPharm (NASDAQ:KMPH)

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder.

Featured Article: Front-End Load

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.